Aarthi Balasubramanyam

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.6kcitations30works6.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(12), Lung Cancer Treatments and Mutations(6), Cardiomyopathy and Myosin Studies(6), Cardiovascular Function and Risk Factors(4), RNA modifications and cancer(4)

Publications30 total

LBP-039 Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trial
Journal of Hepatology·2024· 6 cited
Patient-Level Artificial Intelligence–Enhanced Electrocardiography in Hypertrophic Cardiomyopathy
JACC Advances·2023· 21 citedOpen Access
Improvement in Multi-Domain Patient-Reported Outcome Scores With Mavacamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From the VALOR-HCM Study
Heart Lung and Circulation·2023Open Access
IMPROVEMENT IN MULTI-DOMAIN PATIENT-REPORTED OUTCOME SCORES WITH MAVACAMTEN TREATMENT IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM THE VALOR-HCM STUDY
Journal of the American College of Cardiology·2023Open Access
Abstract 13567: Impact of Mavacamten on Artificial Intelligence Electrocardiographic Diagnosis of Hypertrophic Cardiomyopathy in the EXPLORER-HCM Trial
Circulation·2022
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks
Circulation·2022· 84 cited
Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA
Cancers·2022· 6 citedOpen Access
Assessment of Disease Status and Treatment Response With Artificial Intelligence−Enhanced Electrocardiography in Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology·2022· 38 citedOpen Access
Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer
BMC Cancer·2020· 15 citedOpen Access
Abstract 728: Early assessment of treatment effect in small cell lung cancer (SCLC) via ctDNA analysis
Cancer Research·2020
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I–IV Non–Small Cell Lung Cancer
Journal of Molecular Diagnostics·2019· 52 citedOpen Access
Longitudinal plasma monitoring of subjects treated with EGFR-TKIs allows better understanding of evolution of acquired resistance and can inform optimal treatment strategies
Annals of Oncology·2018Open Access
Identification of subjects with locally advanced lung cancer who are likely to respond to standard-of-care chemoradiotherapy by a longitudinal monitoring of circulating tumor DNA (ctDNA) using a comprehensive ultra-sensitive NGS assay
Annals of Oncology·2018Open Access
Ecological diversity indices as measurements of tumor heterogeneity correlates with clinical outcomes in late stage small cell lung cancer (SCLC)
Annals of Oncology·2018· 1 citedOpen Access
Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.
Journal of Clinical Oncology·2018· 1 cited
Early assessment of treatment effect in advanced lung adenocarcinoma via longitudinal ctDNA analysis.
Journal of Clinical Oncology·2018
Longitudinal ctDNA analysis to enable early assessment of prognosis in lung adenocarcinoma in the absence of matched tissue biopsy.
Journal of Clinical Oncology·2018
Early assessment of therapy response in small cell lung cancer via longitudinal ctDNA analysis.
Journal of Clinical Oncology·2018· 1 cited
OA 10.06 Longitudinal Mutation Monitoring in Plasma by Deep Sequencing as a Potential Predictor of Disease Progression in NSCLC
Journal of Thoracic Oncology·2017
Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).
Journal of Clinical Oncology·2017· 56 cited
page 1 of 2Next →

Frequent Co-authors

Stephanie J. Yaung(13), John F. Palma(12), Hans-Peter Adams(7), Alexander F. Lovejoy(7), Nalin Tikoo(7), Christine Ju(7), Felix Herth(7), Birgit Wehnl(7), Thomas Muley(7), Corinna Woestmann(5), Xiaoju Max(5), Michael Meister(5), Andrew Wang(4), Amy J. Sehnert(4), Sebastian Froehler(4), Bernd Hinzmann(4), Amrita Pati(4), N. Tikoo(4), Felix Lasitschka(4), D. Klass(4)